ENTIA BIOSCIENCES http://www.entiabio.com/ Recent News en GROH® Beauty Line Wins Two Readers' Choice Awards http://www.entiabio.com/content/readMore1/infobox/news/template/default/active_id/59 Entia Biosciences, Inc. and its wholly owned subsidiary Total Nutraceutical Solutions (TNS) has been notified that its GROH® Ergo Boost All-natural Hair and scalp conditioning treatment has received Readers' Choice awards in both the women's and men's hair care product categories from Beauty Launchpad magazine. 2014-02-13 GROH® Reaches Important Milestone with Strategic Partner Mario Tricoci Salon Group http://www.entiabio.com/content/readMore1/infobox/news/template/default/active_id/58 Entia Biosciences, Inc. and its wholly owned subsidiary Total Nutraceutical Solutions (TNS) today announced that the Mario Tricoci Group of salons and day spas, a leading member of the Elizabeth Arden Red Door salon and spa network, will officially launch the entire GROH® Ergo Boost product and professional services line on February 1st, 2014. 2014-01-23 Entia Biosciences Closes Series A Financing http://www.entiabio.com/content/readMore1/infobox/news/template/default/active_id/57 Entia Biosciences, Inc. announced today that it has successfully closed its $1,500,000 Series A Convertible Preferred offering with significant participation from new investors. 2013-11-13 Expanded GROH® line of natural beauty products to be launched at Intercoiffure America/Canada http://www.entiabio.com/content/readMore1/infobox/news/template/default/active_id/56 Total Nutraceutical Solutions, the wholly-owned consumer products subsidiary of Entia Biosciences, today announced that it will be launching its GROH Ergo Boost® line of all natural Professional Service and Consumer beauty products for the salon industry at the Fall Atelier Intercoiffure America/Canada on October 20th and 21st. 2013-10-17 Entia Biosciences Announces Participation at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th http://www.entiabio.com/content/readMore1/infobox/news/template/default/active_id/55 Entia Biosciences today announced it will be featured as a presenting company at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2013, at the Millennium Broadway Hotel in New York City. 2013-09-03 Entia Biosciences Completes Parkinson's Disease Study http://www.entiabio.com/content/readMore1/infobox/news/template/default/active_id/54 Entia Biosciences, Inc. has completed a Parkinson’s disease study in the Neurochemistry Laboratory of Dr. Jack Rogers at Massachusetts General Hospital , Charlestown, MA. 2013-08-26 Entia Files PCT Patent on Athletic Performance http://www.entiabio.com/content/readMore1/infobox/news/template/default/active_id/53 Entia Biosciences announced today that it has filed a PCT patent covering the use of Ergothioneine (Ergo) and/or Vitamin D2 (Ergocalciferol) to physiologically support and improve athletic performance. 2013-07-03 Entia's Organic Vitamin D Enrichment Process Receives US Patent http://www.entiabio.com/content/readMore1/infobox/news/template/default/active_id/52 Entia Biosciences, Inc. announced today that it was notified by its licensor, The Penn State Research Foundation, that the patent entitled "Methods and Compositions for Improving the Nutritional Content of Mushrooms and Fungi" was issued as US Patent number 8,337,921. 2013-06-17 Entia hires director of marketing for medical foods and consumer products http://www.entiabio.com/content/readMore1/infobox/news/template/default/active_id/51 Entia Biosciences, Inc. announced today it has hired Sabrina Jetton to spearhead the Company's product innovation, communications, and branding initiatives as Director of Marketing. 2013-05-15 Entia Biosciences Inc Receives Notices Of Allowance For Ergothioneine And Genetic Transporter Patents From United States, Canada And Israel http://www.entiabio.com/content/readMore1/infobox/news/template/default/active_id/50 Entia Biosciences has now received three Patent Notices of Allowance covering the use of Ergothioneine and its genetic transporter in the treatment of a wide variety of diseases, including those affecting the immune and central nervous systems. 2013-04-02